Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria – a systematic review for the EAACI biologicals guidelines

Filename 412. Agache et al., Eff and saf. Oma EAACI biol, Allergy 2021.pdf
Filesize 697 KB
Version o.412
Date added March 17, 2021
Downloaded 0 times
Category Original Work
Tags Chronic idiopathic urticaria, chronic spontaneous urticaria, itch severity score, omalizumab, Urticaria Activity Score
Authors Agache, I., Rocha, C., Pereira, A., Song, Y., Alonso-Coello, P., Solà, I., Beltran, J., Posso, M., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O., and Jutel, M.
Citation Agache, I., Rocha, C., Pereira, A., Song, Y., Alonso-Coello, P., Solà, I., Beltran, J., Posso, M., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O., and Jutel, M.: Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria – a systematic review for the EAACI biologicals guidelines. Allergy 2021: 76; 59-70.
Corresponding authors Agache, I.
DocNum o.412
DocType PDF
IF TBD (IF 2020: 13.15)
Publisher Allergy
ReleaseDate 2021

This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs includ- ing 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not result in clinically meaningful improve- ment (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) −5; 95%CI −7.75 to −2.25), and the itch severity score (ISS)7 (MD −2.15; 95% CI −3.2 to −1.1) does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD −2.01; 95%CI −3.22 to −0.81) and decreases (moderate cer- tainty) rescue medication use (MD −1.68; 95%CI −2.95 to −0.4). Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD −11.05; 95%CI −12.87 to −9.24), the ISS7 (MD −4.45; 95%CI −5.39 to −3.51), and QoL (high certainty) (DLQI; MD −4.03; 95% CI −5.56 to −2.5) and decreases (moderate certainty) rescue medication use (MD −2.04; 95%CI −3.19 to −0.88) and drug-related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).

(Last update: 08.2021)

Number of publications (original work and reviews) in peer-reviewed journals: 636
Number of original publications in peer-reviewed journals: 462
Number of reviews in peer-reviewed journals: 174
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: 3834,12
Cumulative IF for original publications in peer-reviewed journals: 3043,14
Cumulative IF for reviews in peer-reviewed journals: 790,98
Citations, Hirsch index: (view on Web of Science) 26429